Orthopedic Biomaterial Market, By Material Type (Glass-ceramic & Bioactive Glasses, Calcium Phosphate Cements, Polymer, Metals, Composites), By Application (Joint Replacement, Spine Implants, Orthobiologics, Viscosupplementation, Bio-resorbable Tissue Fixation, Others), By End User (Hospitals, Orthopedic Clinics, Others), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

Published In : Oct 2023

Code : CMI4474

Pages :188

Formats :

Excel and PDF

Industry : Medical Devices

Market News

Global Orthopedic Biomaterial Market - Key Developments

In September 2021, Stryker Corporation launched the Citrelock Tendon Fixation Device System. The novel method offers surgeons a distinct design via a tendon thread that incorporates Citregen, a resorbable technology with unique chemical and mechanical capabilities for orthopedic surgical applications.
In February 2022, Bonalive Biomaterials Ltd., a medical device company based in Finland, announced that the U.S. Food and Drug Administration's Center for Devices and Radiological Health has determined that Bonalive Orthopaedics granules, made of a unique S53P4 bioactive glass, qualify for designation as a breakthrough device.
In March 2022, Synergy Biomedical, LLC, a provider of revolutionary biomaterial solutions, announced the launch of BIOSPHERE FLEX SP EXTREMITIES, a synthetic bioactive bone graft. BIOSPHERE FLEX SP Extremities is a sheet putty consisting of unique spherical bioactive glass grains mixed with a porous collagen and sodium hyaluronate carrier that employs Synergy's exclusive BIOSPHERE Technology. This product complements the Synergy FLEX sheet putty product line. Flex SP Extremities intends to be a key player in the Upper and Lower Extremity markets.

Global Orthopedic Biomaterial Market-Key Trends

Increasing Mergers and Acquisitions: Various market players are engaged in adopting strategies such as mergers and acquisitions, which are expected to drive market growth over the forecast period. For instance, in February 2020, Olympus Corporation, a medical technology company, announced that it had acquired FH ORTHO SAS, an international orthopedic company headquartered in Heimsbrunn, France, following the close of a definitive agreement the two companies signed in the summer of 2020. The acquisition underscores Olympus’ commitment to expanding in the growing field of medical devices for orthopedic minimally invasive surgery (MIS) both organically and through mergers and acquisitions, with the overarching goal of developing innovative solutions that improve clinical outcomes, reduce overall costs, and enhance quality of life for patients.